NEUROGENE INC

Insight on Neurogene’s insider selling: 10b5‑1 plan sales stay modest, indicating liquidity needs, not confidence loss, while the stock’s growth prospects remain strong.

Neurogene CFO Christine Mikail sells 4,800 shares under a pre‑approved plan; assess why insiders trade while the stock rises on FDA breakthrough news.